tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HK:9926 Stock Latest News

Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
Company AnnouncementsAkeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
7d ago
Akeso announces NMPA acceptance of second NDA for gumokimab
PremiumThe Fly
Akeso announces NMPA acceptance of second NDA for gumokimab
14d ago
Akeso downgraded to Hold from Buy at Daiwa
PremiumThe Fly
Akeso downgraded to Hold from Buy at Daiwa
1M ago
Akeso Restructures MAb Manufacturing Deal as Joint Venture Becomes Connected Transaction
PremiumCompany Announcements
Akeso Restructures MAb Manufacturing Deal as Joint Venture Becomes Connected Transaction
1M ago
Akeso’s Innovative Drugs Included in China’s 2025 NRDL
PremiumCompany Announcements
Akeso’s Innovative Drugs Included in China’s 2025 NRDL
2M ago
Akeso, Inc. Advances Cancer Treatment with New Phase I Study on AK137
PremiumCompany AnnouncementsAkeso, Inc. Advances Cancer Treatment with New Phase I Study on AK137
3M ago
9926
Akeso, Inc. Launches Promising Phase II Study for NSCLC Treatment
Premium
Company Announcements
Akeso, Inc. Launches Promising Phase II Study for NSCLC Treatment
3M ago
9926
Akeso, Inc. Advances Cancer Treatment with Promising AK146D1 Study
Premium
Company Announcements
Akeso, Inc. Advances Cancer Treatment with Promising AK146D1 Study
3M ago
9926
Akeso’s New Phase II Study on Advanced Pancreatic Cancer: A Potential Game-Changer?
PremiumCompany Announcements
Akeso’s New Phase II Study on Advanced Pancreatic Cancer: A Potential Game-Changer?
3M ago
9926
Akeso’s Innovative Cancer Treatment Study: A Promising Update for Investors
PremiumCompany Announcements
Akeso’s Innovative Cancer Treatment Study: A Promising Update for Investors
3M ago
9926
Akeso and TransThera Sciences Launch Promising Phase II Study for Advanced Liver Cancer
PremiumCompany Announcements
Akeso and TransThera Sciences Launch Promising Phase II Study for Advanced Liver Cancer
3M ago
Akeso, Inc. Advances Ebronucimab Study: Market and Clinical Insights
PremiumCompany Announcements
Akeso, Inc. Advances Ebronucimab Study: Market and Clinical Insights
3M ago
9926
Akeso’s Phase III Clinical Study: A Potential Game-Changer in Gastric Cancer Treatment
PremiumCompany AnnouncementsAkeso’s Phase III Clinical Study: A Potential Game-Changer in Gastric Cancer Treatment
3M ago
9926
Akeso, Inc. Launches Promising Phase III Study for Lung Cancer Treatment
Premium
Company Announcements
Akeso, Inc. Launches Promising Phase III Study for Lung Cancer Treatment
3M ago
9926
Akeso’s Promising AK129 Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Akeso’s Promising AK129 Study: A Potential Game-Changer in Cancer Treatment
3M ago
9926
Akeso, Inc. Launches Phase II Study on Promising HCC Treatment
PremiumCompany Announcements
Akeso, Inc. Launches Phase II Study on Promising HCC Treatment
3M ago
9926
Akeso’s Phase 3 Trial: A Potential Game-Changer in NSCLC Treatment
PremiumCompany Announcements
Akeso’s Phase 3 Trial: A Potential Game-Changer in NSCLC Treatment
3M ago
9926
Akeso, Inc.’s New Phase III Study: A Potential Game-Changer in Pancreatic Cancer Treatment?
PremiumCompany Announcements
Akeso, Inc.’s New Phase III Study: A Potential Game-Changer in Pancreatic Cancer Treatment?
3M ago
9926
Akeso, Inc. Launches Promising Phase III Study for Metastatic Colorectal Cancer Treatment
PremiumCompany Announcements
Akeso, Inc. Launches Promising Phase III Study for Metastatic Colorectal Cancer Treatment
3M ago
9926
Akeso, Inc. Launches Promising Phase I Study on AK139
PremiumCompany AnnouncementsAkeso, Inc. Launches Promising Phase I Study on AK139
3M ago
9926
Akeso, Inc. Advances Cancer Treatment with New Clinical Study on AK130 and AK112
Premium
Company Announcements
Akeso, Inc. Advances Cancer Treatment with New Clinical Study on AK130 and AK112
3M ago
9926
Akeso’s Promising Phase II Study on Combination Therapy for Ovarian Cancer
Premium
Company Announcements
Akeso’s Promising Phase II Study on Combination Therapy for Ovarian Cancer
3M ago
9926

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >